Simulations Plus: A Credible Drug-Modeling Specialist, Now Priced as a Near-Cash Deal Stock

On fundamentals alone, the right label for Simulations Plus is a company in transition: not a pure compounding software story, and not a broken asset either. The software franchises remain useful, the regulatory wind is favorable, cash conversion has historically been respectable, and balance-sheet risk has been low relative to most software peers because the company funded growth partly from cash and prior equity raises rather than leverage. But the quality of growth got messier after Pro-ficiency, and the public market had already been questioning whether SLP’s future multiple should look like premium life-sciences software or more like a mixed software-services specialty vendor. The Altaris deal arrived before that argument was fully settled.

My bottom line has two layers. As a business, SLP still has credible scientific assets and sits in a favorable regulatory lane. As a stock on 2026-06-26, it is no longer mainly an expression of those fundamentals. It is a near-cash event security with limited upside to $18.50 if the deal closes and meaningful downside if it breaks and the market re-prices the company back on standalone growth, mix, and multiple. The clean qualitative portrait is a company in transition, and at the current price the equity is best understood as a priced-to-close transaction, not an open-ended growth investment.

Company vertical history

Simulations Plus exists because early drug-development decisions are expensive and slow, and often wrong when they lean too heavily on wet-lab iteration. The company was incorporated in California on July 17, 1996. Founder Walter Woltosz, who later served as chairman and chief executive officer for decades, brought a background in pharmacokinetics and machine-learning methodology for pharmaceutical research; the 2026 proxy still described him as cofounder and a long-time scientific architect of the business. The company’s original purpose was practical: help pharmaceutical researchers model absorption, distribution, metabolism, excretion, toxicity, and dosing behavior before they spent more time and money advancing a candidate.

That origin shaped the company more than the ticker ever did. SLP did not start as a contract-research shop that later wrapped software around itself. It started as scientific software and expanded outward into services when customers needed more help turning the science into regulatory decisions and project execution. The order matters because it explains where the best economics still sit. Even after years of M&A, the most attractive part of the business remains the licensed scientific engine, not the hours billed around it.

The listing path was unusual only in the way common to many older micro-cap software names. SLP’s common stock was sold in its 1996 IPO at $1.25 per share on a post-split basis, and the company moved through a long public life before uplisting to the Nasdaq Global Select Market effective May 13, 2021. This is the path of a niche scientific company that spent years building credibility before the market rewarded it with a growth multiple, not a venture-backed unicorn that hit the public market at peak enthusiasm.

Its history reads best in four stages.

The first stage, from founding through roughly 2013, was product validation. The company had to prove that specialized biosimulation software could win budgets in a conservative, highly technical pharmaceutical market. What it lacked in scale it made up in specificity. Tools like GastroPlus and ADMET Predictor addressed concrete bottlenecks, and the company built customer trust through technical support, training, seminars, and reproducibility rather than brand marketing. The market treated SLP as a tiny specialty software vendor; the lasting result was scientific credibility and an installed base, not yet a broad platform.

The second stage, from 2014 through 2020, was capability expansion via selective acquisitions. Cognigen brought clinical pharmacology and pharmacometrics services in 2014 and was expected at the time to add about $5 million of revenue, nearly doubling headcount from 30 to 65. DILIsym followed in 2017, giving the company a recognized capability in drug-induced liver-injury simulation. Lixoft in 2020 broadened the software stack deeper into pharmacometrics with MonolixSuite and expanded the European footprint. This was the period when SLP stopped being one product family plus consulting and began to look like a connected set of scientific tools across discovery, development, and regulatory use cases.

The third stage, from 2020 through 2023, was the public-market re-rating and balance-sheet reinforcement. In August 2020 the company priced a $100 million underwritten common-stock offering, giving it much more financial capacity. Revenue rose from about $41.6 million in fiscal 2020 to $46.5 million in 2021, then to $53.9 million in 2022 and $59.6 million in 2023. The stock rode a broader software and life-sciences enthusiasm cycle and eventually reached an all-time high of $90.92 in February 2021, well before the underlying business could permanently validate that multiple. This stage left SLP with cash, a broader investor audience, and room to buy more assets, but it also raised the market’s expectations.

The fourth stage, from 2023 to the current date, was strategic broadening, followed by public-market doubt and then a take-private solution. Immunetrics was acquired in June 2023 to deepen QSP in oncology, immunology, and autoimmune disease. Pro-ficiency was acquired in June 2024 for about $100 million in cash to add simulation-enabled clinical-operations, launch training, and communications capabilities across later stages of the drug-development continuum; management argued that this doubled TAM by adding a further $4 billion opportunity to an existing $4 billion biosimulation market. On paper, that move made the platform broader. In the numbers, though, it lowered the neatness of the model. Fiscal 2025 revenue rose 13% to about $79.2 million, but gross margin fell to 58% from 62%, and the company said the margin decline was largely attributable to Pro-ficiency underperformance. It also recorded $77.2 million of impairment charges during 2025. That sequence is the clearest reason the company’s premium-growth image weakened before Altaris arrived.

A major management node sits inside that arc. Founder Walter Woltosz stepped down as chief executive in June 2018, and Shawn O’Connor became CEO. O’Connor’s background was not random. He had previously led Entelos and Pharsight, two businesses deeply connected to software and model-based drug development. The board later shifted again, with Daniel Weiner becoming chairman in December 2024 while Woltosz remained a director and the largest insider shareholder group together with Virginia Woltosz. That succession says something useful: SLP moved from founder-build mode into operator-platform mode without entirely severing the scientific founding DNA.

Several key nodes still shape the company today.

The Cognigen deal in 2014 mattered because it made services a permanent part of the operating model rather than a support appendage. It expanded client relationships and brought the company closer to clinical data and regulatory work, but it also planted the seed of future mix complexity. In hindsight it was underrated strategically, because it changed the company’s trajectory toward a broader platform.

The DILIsym acquisition in 2017 mattered because it brought in a highly differentiated scientific niche with regulatory relevance. That was more than revenue. It strengthened SLP’s credibility in systems toxicology and later helped the company position itself around NAMs and computational safety. This node still matters because the FDA and NIEHS collaborations in 2026 sit naturally on top of the company’s toxicology and mechanistic-modeling capabilities.

The Lixoft acquisition in 2020 was one of the company’s most successful strategic expansions. It added MonolixSuite, a recognized pharmacometrics software family with strong software economics and a European presence. This deal helped make SLP look more like a genuine portfolio of scientific engines rather than a one-product house. It also improved the software side of the revenue mix in the early 2020s.

The Pro-ficiency acquisition in 2024 is the hinge point. Management framed it as an end-to-end expansion from preclinical protocols through commercialization, with cross-selling and TAM expansion. The market judged it against margin quality and integration execution. Because the 2025 annual report explicitly tied the gross-margin decline to Pro-ficiency underperformance and recorded large impairment charges after underperformance relative to purchase-price assumptions, the transaction remains both the strategic ambition and the financial scar of the recent period. In hindsight, it was neither noise nor fatal. It genuinely changed the company’s earnings profile and likely made the company easier to value as a private platform combination than as a premium standalone public software stock.

The January 2026 Investor Day was a more subtle node. Management told the market it wanted to evolve from leading point tools into an integrated, AI-enabled ecosystem, then reinforced that story in strategic collaboration announcements with large pharma and in a March 2026 panel on responsible AI in MIDD. The pitch was not “we are adding AI” in the lazy sense. The company wants AI agents embedded inside validated engines and controlled by standards for transparency, reproducibility, and governance. Whether or not investors would have fully re-rated that story on a standalone basis will now never be cleanly observed in public markets because the Altaris agreement intervened.

The June 2026 Altaris sale announcement is the most consequential capital-markets node since the 2020 equity raise. Altaris agreed to acquire SLP for $18.50 per share in cash and combine it with Chemical Computing Group, another Altaris portfolio company. That is a revealing outcome. Private ownership and combination with another scientific software asset suggest that the strategic buyer saw more value in building a broader computational platform than the public market was willing to capitalize at that moment under SLP’s standalone structure. The market reaction was immediate: the stock jumped to the deal vicinity and largely stayed there.

Financial vertical review

The financial history shows genuine top-line expansion, periodic multiple compression, and a gradual shift from a cleaner software profile toward a broader but less elegant software-plus-services mix. Revenue rose from about $34.0 million in fiscal 2019 to $41.6 million in 2020, $46.5 million in 2021, $53.9 million in 2022, $59.6 million in 2023, $70.0 million in 2024, and about $79.2 million in 2025. That is a real growth record, not a quarterly illusion. But the drivers changed over time. Earlier growth leaned more on scientific software and niche-services expansion; later growth leaned more heavily on acquisitions, especially Pro-ficiency.

The margin record divides neatly into before and after Pro-ficiency. Gross margin was 77.2% in fiscal 2021 and 80% in both 2022 and 2023, then fell to 62% in 2024 and 58% in 2025. Management’s own account matters here. The 2024 margin shift was tied partly to reorganization and acquired-cost mix, while the 2025 annual report said the further decline was largely attributable to Pro-ficiency underperformance. That tells you the problem was not merely accounting noise. The mix got less favorable and the acquired asset did not perform as underwritten. The improvement to 66% in fiscal Q2 2026 is encouraging, but it does not erase the strategic lesson: later-stage services and simulation-enabled training can broaden the platform while diluting the economic purity that previously justified premium multiples.

Earnings quality has to be read carefully because 2025 GAAP numbers were distorted by the impairment. Fiscal 2024 net income was about $10.0 million and fiscal 2023 net income was about $10.0 million, while fiscal 2025 reported a net loss of $64.7 million after $77.2 million of impairment charges. On a normalized basis management pointed investors to adjusted net income of $20.7 million and adjusted diluted EPS of $1.03 for fiscal 2025. That does not mean the impairment should be ignored; it means it should be interpreted correctly. The impairment was non-cash, but it was also the accounting recognition that one part of the company had been bought at assumptions that no longer held.

Cash conversion has been better than the raw 2025 income statement suggests. Net cash provided by operating activities was $21.9 million in fiscal 2023, $13.3 million in fiscal 2024, and $18.1 million in fiscal 2025. Against GAAP net income those years look uneven because 2025 was depressed by the impairment, but the broad message is that the business remained cash-generative even through a messy integration period. Capitalized software development ran roughly $3.2 million in 2024 and $3.0 million in 2025, which means owner earnings are meaningfully lower than EBITDA but still positive and solid. It is a profitable niche software-and-services company whose public multiple had outrun the neatness of its later mix, not a cash-burning “story stock.”

The balance sheet has historically been more conservative than most software peers. The company used the 2020 equity raise to increase financial flexibility, not to support a levered roll-up. The 2024 annual report showed $70.0 million of revenue on a largely ungeared balance sheet, and the market’s current enterprise value sits below market capitalization, implying continuing net cash even after the Pro-ficiency outlay. Third-party market data on 2026-06-25 showed market cap of roughly $366.5 million and enterprise value of about $325.2 million. I would not lean heavily on the precise net-cash number without the latest 10-Q balance sheet in front of me, but the broad point is clear: financial soundness is not the central risk here. Execution and mix are.

Returns on capital were once flattered by the simplicity of the pre-Pro-ficiency model and by modest capital intensity. They weakened once acquired intangibles and lower-margin revenue played a larger role. The best way to think about this is structural rather than formulaic: the original SLP model converted a niche scientific software position into strong margins; the recent SLP model tried to convert platform breadth into broader customer relevance. The market had already decided those are not worth the same multiple.

Price and valuation history

SLP’s share-price history has four recognizable phases. The first was a long, thinly followed specialty-software period in which the stock mostly reflected small-company execution and scientific relevance. The second was the 2020–2021 re-rating, when software liquidity, healthcare-tech enthusiasm, and SLP’s own revenue growth pushed the shares to an all-time high of $90.92 in February 2021. The third was the unwind from 2021 through mid-2026, in which multiple compression, slower growth, acquisition noise, and margin skepticism steadily brought the stock back into the teens. The fourth began on June 16, 2026, when the Altaris agreement reset price discovery toward the $18.50 cash offer.

The drivers behind those moves changed with the era. The run into 2021 was a classic mix of earnings growth, software multiple expansion, and abundant liquidity. The decline after 2021 was not just “rates went up.” The business itself also became harder to underwrite. Gross margins stepped down, software growth became less consistent, and the large Pro-ficiency acquisition made SLP look less like a pure scientific software vendor. When 2025 impairment charges arrived, they did not create the market’s doubt. They confirmed it.

The market’s valuation label on SLP shifted accordingly. At the 2021 peak it was treated like premium niche vertical software. By 2024–2025 it was more of a “good business, but messier than it used to be” name. By late June 2026 it was closer to a merger arb stub. That is why traditional standalone valuation still matters analytically but explains less of the current share price than the deal mechanics do. The current price is only modestly above where the stock traded immediately after the announcement because the market is pricing a high probability of completion plus a small spread, not re-embracing a growth premium.

On raw current numbers, the stock is not obviously generically cheap. Using third-party market data for June 25, 2026, SLP’s enterprise value was about $325.2 million against a FY2026 revenue guide of $79–82 million, or roughly 4.0x revenue at the midpoint. That multiple is not absurd for niche life-sciences software, but it is not a bargain if the software mix is weaker than expected and if the stock is already being held near an $18.50 takeout price rather than being priced off an open-ended standalone future.

Business model and moat

SLP’s revenue structure is straightforward in headline form and complicated in economic consequences. It now reports software and services rather than the older acquired-division lens. In fiscal 2024, software represented 59% of revenue and services 41%; in fiscal 2025, management reported software revenue of $45.8 million, or 58% of total revenue, and services revenue of $33.4 million, or 42%. In the first half of FY2026 the mix moved toward services again: software was 55% and services 45%, largely because Q1 software was weak before Q2 recovered.

Software and services are not interchangeable dollars. Fiscal 2024 software gross margin was 84% versus 30% for services. That alone explains most of the market’s sensitivity to the software slowdown. A dollar of services can deepen the account, improve switching costs, and help sell more software later. But a dollar of services is also more exposed to utilization, project timing, and labor cost. When software softens and services take the weight, the income statement changes character.

The cost structure reflects that split. Software carries material fixed costs in R&D, scientific support, and some amortization of capitalized software development, but incremental gross margins are very high. Services carry higher variable personnel expense and can be dragged down by pass-through costs, project delays, and acquired-business underutilization. That is why SLP shows operating leverage when software is strong and margin pressure when services lead the mix. It also explains why Pro-ficiency, though strategically broadening, was financially disruptive when it underperformed.

The moat is real, but it is narrower than broad “AI in drug development” language can imply.

The first real moat is scientific credibility in validated modeling domains. Tools such as GastroPlus, MonolixSuite, ADMET Predictor, and DILIsym are not generic productivity software. They are specialized engines used by scientists and regulators to answer highly technical questions. EMA’s PBPK guideline explicitly applies to commercially available platforms as well as in-house platforms, and EMA’s 2025 mechanistic-model guideline explicitly names PBPK and QSP among the covered models. SLP’s long-running funded collaborations with FDA and NIEHS further reinforce that the company is working in domains where validated science, not just user-interface polish, determines adoption.

The second moat is switching cost through workflow familiarity and accumulated model practice. Scientific software can be replaced, but not casually. Teams invest in internal expertise, validation habits, training materials, and regulatory comfort around a specific platform. Lixoft’s MonolixSuite and SLP’s other engines benefit from that. This is also why the company invests so heavily in seminars, workshops, support, and training: those activities are not merely sales expense; they are adoption infrastructure.

The third moat is the combination of software and services inside one customer relationship. This is a double-edged strength. It can protect the installed base because SLP can sell a client a license, help build the model, support the regulatory package, and train broader users. That integrated access creates stickiness and cross-sell potential. But it becomes a marketing moat rather than a pure economic moat if the services side grows mainly because customers need hand-holding the software cannot avoid. The mix data over the last year suggests the advantage is real, but not frictionless.

The fourth moat is regulatory alignment. The company is not a regulator and does not own a legal license. But it does operate in a market where FDA and EMA are moving toward more mechanistic modeling and reduced animal testing, which favors vendors with long regulatory interaction histories and reproducible scientific tooling. That is not a monopoly. Certara benefits from the same tailwind. But it does raise the bar for casual entrants.

Management quality has been mixed in exactly the way the financials suggest. O’Connor brought relevant industry experience from Entelos and Pharsight, and the platform vision he described is strategically coherent. Capital allocation before Pro-ficiency looked disciplined: Lixoft and Immunetrics were science-adjacent and logically additive. The Pro-ficiency deal was bolder. It was not irrational, but the subsequent underperformance and impairment mean management does not get the benefit of the doubt that every adjacency will integrate smoothly. On governance, insider ownership remains meaningful through founder Walter Woltosz, who beneficially owned 16.3% of the company as of December 15, 2025, while all directors and executive officers together owned 19.1%. That alignment is positive. The June 2026 transaction bonuses for executives tied to the Altaris sale also matter, because they remind investors to separate management incentives from minority-holder risk/reward at a tight deal spread.

Industry and cycle

SLP sits in a niche where industry structure is shaped less by commodity pricing and more by scientific trust, regulatory validation, and integration into customer workflow. The broad category is model-informed drug development and related computational safety tools. Growth is being pulled by several forces at once: higher complexity in drug development, cost pressure inside pharma R&D, greater regulator acceptance of mechanistic and quantitative models, and growing emphasis on non-animal methodologies. That combination makes the category more attractive than generic healthcare IT and less cyclical than outsourced trial services.

The industry profit pool sits disproportionately in trusted software platforms and high-value scientific advisory work, not in generic services. Customers pay up when a platform is both technically defensible and already accepted inside internal decision frameworks or regulator interactions. That is why Certara’s scale matters, why Schrödinger can command attention with platform differentiation, and why SLP’s software mix matters so much more than its reported revenue growth taken alone.

The cycle attributes are mixed. This is not a classic macro cycle business, but it is not fully defensive either. It is exposed to biotech funding conditions, pharma budget pacing, project starts, and software renewal timing. Management itself cited an improving funding environment for clients in both Q1 and Q2 FY2026, which implies that some of the demand softness was cyclical or at least budget-timing related rather than purely competitive. At the same time, the regulatory move toward NAMs and MIDD is more structural than cyclical. So SLP lives at the overlap of a structural tailwind and a still-cyclical customer wallet.

Policy and regulation are unusually important here. FDA’s continued MIDD program, the 2025 roadmap to reduce animal testing, and EMA’s current guidance on PBPK, mechanistic models, and NAM adoption are category tailwinds. SLP’s February 2026 extension of FDA and NIEHS research collaborations shows that the company is not just watching those changes from the sidelines. That does not guarantee commercial dominance, but it does make the regulatory direction a genuine demand support rather than marketing garnish.

Geopolitical risk is secondary rather than central. The bigger external variables are biopharma spending, regulatory acceptance pace, and the possibility that large customers expand in-house tools or consolidate on larger vendors. SLP’s recent commentary about tariffs and pricing policy suggests management sees macro policy noise affecting clients, but not in a way that breaks the category’s long-run thesis.

Horizontal competitor analysis

The most useful competitive frame is “what each rival became, and why customers actually pick it,” not “who has the longest feature list.”

Certara is the principal public peer because it is the scaled institutional workflow vendor in model-informed drug development. Its software stack includes Phoenix, Simcyp, Pinnacle 21, D360, CoAuthor, and regulatory tools; it also has a large services base. In fiscal 2025 it generated $418.8 million of revenue with 9% growth, and in Q1 2026 it reported $106.9 million of revenue, including $49.7 million of software revenue and $57.2 million of services revenue. Customers pick Certara when they want scale, broader workflow coverage, strong regulator adjacency, and a vendor already embedded across many parts of the development process. The reason it matters so much to SLP is that it competes head-on in exactly the area SLP wants to own: validated model-informed development tools sold into regulated pharma workflows.

Schrödinger is not a direct PBPK-for-PBPK substitute, but it is an important strategic reference because it shows what a differentiated scientific platform can look like when it combines software with discovery optionality and then layers AI onto that foundation. In 2025 it generated $255.9 million of total revenue, of which $199.5 million was software. Its Q1 2026 software revenue fell 21% because of a planned shift toward hosted licensing, but ACV still rose 12% and management framed the decline as accounting/timing rather than demand collapse. Customers pick Schrödinger for a more physics-based discovery platform, higher-end computational capabilities, and a blend of software and therapeutic upside. Investors price it as a platform with software growth and embedded option value, not as a services-heavy niche specialist.

SLP occupies a tighter niche than either one. Customers pick Simulations Plus when they want scientifically trusted tools in several specific domains, often with a practical services layer and a customer relationship that can move from early discovery to regulatory support. They do not pick it because it is the obvious largest-scale incumbent. Nor do they pick it for platform optionality on the scale of Schrödinger’s drug-discovery portfolio. They pick it because the tools work, the scientists know the workflow, and SLP can be less bureaucratic than the larger vendor. That is a good niche, but it caps how much execution slippage the market will forgive.

Numerically, the comparison is revealing. Certara is much larger and still more balanced between software and services, though its Q1 2026 software grew 7% while services fell 4%. That is almost the mirror image of SLP’s concern: Certara showed that software strength can stabilize the model even when services wobble. Schrödinger’s comparison is different. Its revenue mix is not directly comparable, but its capitalization by the market still reflects belief that strong software economics and differentiated science can justify investment despite GAAP losses. SLP is the smallest of the three and the most sensitive to one acquisition changing its public-profile economics.

SLP’s niche is therefore that of a specialist challenger with unusually strong science for its size, but without the scale buffer of Certara or the discovery-platform glamour of Schrödinger. It filled the gap between point-tool excellence and full-service scientific support. The risk is that this middle ground is powerful when execution is tight and awkward when the services mix expands faster than software. In a tightening budget environment, some customers may consolidate spend onto larger workflow vendors or do more model integration in-house. In a more supportive environment, SLP can still win because its tools are credible and its scientists are close to the work. That makes the current weakness more likely mixed than purely structural. But mixed is not the same as solved.

Current fundamentals and bull bear divergence

The last four reported quarters show a business that is still growing on a trailing basis but no longer growing cleanly. Fiscal Q3 2025 revenue was up 20% to $61.7 million for the first nine months, though that period also included a $77.2 million non-cash impairment. Fiscal Q1 2026 then disappointed on mix: total revenue fell 3% to $18.4 million, software fell 17% to $8.9 million, and services rose 16% to $9.5 million. Fiscal Q2 2026 partially repaired the picture: revenue grew 8% to $24.3 million, software grew 9% to $14.6 million, services grew 8% to $9.7 million, and gross margin improved to 66%. Across the six months, however, software was still down 3% while services were up 12%. The market was right to focus on the software line.

Management’s guidance has become less ambitious but still not recessionary. The company reaffirmed FY2026 revenue guidance of $79–82 million in Q1 and kept that range in Q2, implying flat to low-single-digit growth. It cut adjusted diluted EPS guidance in Q2 to $0.75–0.85 from $1.03–1.10, but explicitly said the cut reflected a higher expected tax rate, not a reduction in revenue or EBITDA guidance. That distinction matters. It tells you the operating story improved from Q1 to Q2, but not enough to restore the old premium-growth image.

The market today is trading two things at once. The first is the June 2026 cash merger value. The second, underneath it, is the unresolved standalone question of whether SLP’s software softness was a temporary product-and-renewal air pocket or a sign that the company is becoming structurally more services-heavy. If the deal had not arrived, July 9, 2026 earnings would likely have been a major referendum on that question. With the deal in place, the same earnings still matter, but more as a check on downside if the transaction breaks.

The bull case rests on concrete evidence. Regulatory winds remain favorable, as FDA and EMA continue to formalize support for model-informed and non-animal approaches. SLP’s own federal collaborations were extended in February 2026, which supports the view that its science remains relevant. Q2 2026 showed that software weakness was not universal across the portfolio, with growth driven by discovery and development solutions while bookings and backlog improved. Management’s AI ecosystem push is also not empty branding: the March 2026 strategic collaboration programs with large pharmaceutical companies are built around embedding internally developed AI agents inside validated scientific workflows, which is a sensible way to monetize AI in a regulated field.

The bear case also rests on evidence. Software, the highest-quality revenue stream, still declined in the first half of FY2026. The company itself said Q1 weakness came from expected declines in clinical operations and development software, and Q2 again cited an anticipated decline in clinical operations software. That suggests the problem is not a single quarter’s billing timing. Second, Pro-ficiency broadened the platform but clearly hurt margin quality and produced impairment charges, which weakens confidence in management’s expansion-by-acquisition playbook. Third, the Altaris sale itself can be read as a verdict: the public market was no longer the most natural home for this transition story, especially after the company had already been pulled back into the mid-teens.

Valuation analysis

Standalone valuation and current stock pricing have to be separated.

Historically, SLP’s valuation center has already compressed sharply from the 2021 peak. The difference is not just investor style rotation. The underlying business changed. When the company was smaller, more software-heavy, and cleaner, the market rewarded it like scarce vertical software. After Pro-ficiency and the 2025 impairment, the public market treated it more cautiously. That shift looks durable unless software returns to clearly leading growth again.

Peer valuation does not rescue the stock. Certara, despite much larger scale, is itself no longer priced like a high-flying software compounder. Schrödinger still trades on platform expectations but with a very different business model and balance-sheet profile. SLP therefore does not deserve a simple “peer-average” premium. The right conclusion is more modest: on a standalone basis, SLP probably deserves a valuation between a scaled workflow incumbent and a higher-risk, higher-optionality computation platform, with a discount for its recent mix instability.

Cash-flow passthrough is the key discipline here. Over the past three fiscal years, operating cash flow held well above what the 2025 GAAP loss would imply because the impairment was non-cash: operating cash flow was $21.9 million in 2023, $13.3 million in 2024, and $18.1 million in 2025, while 2025 GAAP net income was a loss of $64.7 million after impairment. Capitalized software development ran around $3.2 million in 2024 and $3.0 million in 2025, so true owner earnings are lower than adjusted EBITDA and lower than management’s adjusted EPS. I therefore prefer an owner-earnings and EV/revenue hybrid framework rather than headline P/E alone.

Valuation scenarios

This is valuation-scenario analysis within a research framework, not investment advice.

The business reading behind the numbers is simple. If SLP proves it can keep software near 60% of revenue and sustain high-20s EBITDA margins, the standalone equity can justify a mid-teens to upper-teens value. If software remains inconsistent and services do more of the work, a low-to-mid teens stand-alone valuation is more realistic. The cash offer at $18.50 effectively prices the optimistic end of standalone recovery plus private-combination synergies that public holders will not capture if they buy today.

Expectation-gap analysis is therefore unusual. The market is not currently pricing heroic standalone growth. It is pricing a high probability that Altaris closes. The real expectation gap is on the downside: many holders may implicitly assume that if the deal failed, the stock would remain near today’s level because the business is fine. I do not think that follows. Without the transaction, investors would have to reopen the questions around Q1 software weakness, Pro-ficiency economics, and what multiple a mixed software-services scientific vendor deserves.

The margin-of-safety recheck is clear. At the current price, there is no standalone margin of safety. The price sits above what I consider a comfortable buy zone on conservative assumptions. The most fragile assumption in my base case is not revenue growth by itself; it is software mix recovery. If software stays stuck near the mid-50s as a share of revenue and services continue to do the incremental work, the base valuation leans quickly toward the conservative range. On a flat-earnings, no-rerating case, the prospective return from today’s price is poor unless one is explicitly playing for the deal spread. The verdict on margin of safety is none.

Risk analysis

The largest business risk is that the software slowdown proves more structural than temporary. Probability is medium; impact is high. The observable indicators are software revenue growth, software mix, and clinical-operations software commentary over the next two quarters. The transmission path is direct: lower software mix means lower gross margin, weaker EBITDA leverage, and a permanently lower valuation center. Q1 FY2026 already showed this risk in raw form, and Q2 only partly neutralized it.

The second major risk is execution risk around platform breadth. Probability is medium; impact is high. Pro-ficiency was bought to double TAM and broaden the continuum. Instead, 2025 gross-margin deterioration and impairment charges showed how fast a strategic adjacency can hurt economics if utilization or cross-sell underperforms. The indicator here is not rhetoric about synergies. It is whether margins can stay in the mid-60s on quarterly gross margin and whether services growth is being led by development solutions rather than lower-quality pass-through activity.

The third major risk is event risk from the Altaris transaction. Probability is low-to-medium; impact is high. If the deal closes as planned, upside from the current price is limited to the remaining spread. If it breaks, the stock is unlikely to be defended by the cash offer and would probably revert toward a standalone valuation based on slowing software growth and a lower public-market multiple. The observable indicators are merger-proxy progress, regulatory milestones, and any adverse changes in operating performance before close.

The fourth risk is valuation and style risk even absent a broken deal. Probability is medium; impact is medium-to-high. Small life-sciences software names with mixed revenue quality can lose premium multiples quickly when growth slows. SLP’s history since 2021 is evidence enough. The indicator is not the market mood in general; it is whether investors start valuing the company primarily on software revenue and margin quality rather than total revenue growth.

The fifth risk is competitive consolidation. Probability is medium; impact is medium. Larger vendors such as Certara can absorb broader workflow budgets, while some large pharma customers can build more in-house tooling around specific use cases. The signal to watch is not customer count disclosure, which SLP does not fully provide, but whether software renewals, backlog, and new-logo activity remain strong enough to offset pressure in clinical-operations software.

Catalysts and tracking indicators

Positive catalysts are still possible, even with the deal in place. The most obvious is transaction completion at $18.50 per share in the second half of 2026. The second is a strong fiscal Q3 2026 print on July 9 that shows software growth broadening beyond discovery and development and confirms that Q1 was a trough rather than a trend. The third is evidence that AI-enabled workflow collaborations have begun to create real commercial traction rather than just strategic positioning. The fourth is further regulator-linked validation, such as expanded funded collaborations or clearer commercial pull from NAM-related workflows.

Negative catalysts are equally tangible. A weak Q3 with another poor software mix would increase the perceived downside if the deal breaks. Any regulatory or shareholder complication that delays closing would widen the arbitrage spread. Another visible sign of Pro-ficiency underperformance or services-led growth would also remind the market why the stock de-rated in the first place.

Tracking dashboard

Why these matter is more important than the thresholds themselves. Software growth and software mix tell you whether the moat-bearing part of the model is winning. Gross margin and EBITDA margin tell you whether platform breadth is paying for itself. Backlog and new-logo commentary help separate timing noise from a real demand problem. The deal spread tells you what the market thinks about closing risk in real time. Regulators and AI announcements matter only when they change workflow adoption or commercial behavior; otherwise they are narrative fuel, not economics.

Cross synthesis summary

Looking vertically across its whole life, Simulations Plus has proven one capability beyond doubt: it can build or assemble scientifically credible modeling tools that matter inside real pharmaceutical decisions. That is not trivial. Plenty of industry software companies sell process convenience. Fewer become part of the scientific argument a customer makes to itself or to a regulator. SLP did that first in narrow pharmacokinetic and ADMET workflows, then broadened through pharmacometrics and systems toxicology, and later tried to push outward into a more continuous software-and-services platform across the drug-development lifecycle. The company’s success did not come from financial leverage or from one lucky cycle. It came from technical specificity, patient market-building, and a willingness to stay close to where drug-development uncertainty is expensive.

The company’s recent problem is no mystery. Past public-market success came partly from the era’s willingness to pay rich multiples for specialized software, and partly from SLP’s then-cleaner financial profile. Those success factors are no longer all present. The regulatory tailwind is still here, perhaps stronger than before. The scientific relevance is still here. The trouble is that platform breadth now carries more execution risk, and the labor-heavy parts of the platform have taken a bigger share of the reported revenue. The market did not need to conclude that SLP’s science was weak to conclude that the old multiple was too high. It only needed to conclude that the growth story had become less pure and less predictable.

Horizontally, SLP’s real advantage over competitors remains scientific intimacy and niche tool strength, not dominant scale. Against Certara it lacks breadth and institutional heft. Against Schrödinger it lacks platform glamour and discovery upside. But it still offers customers a credible middle path: validated engines, hands-on experts, and enough breadth to be useful across discovery and development. I do not think its recent weaknesses are fully structural. Q2 2026 was too good for that. I also do not think they are fully temporary. The software decline in Q1 and the ongoing weakness in clinical-operations software say the business is still proving what the post-Pro-ficiency steady state looks like.

As for valuation, the public market is no longer primarily rewarding the company for future success. It is rewarding holders with a near-cash exit if the deal closes. That subtle difference is everything. A buyer of SLP at $18.14 is not getting open-ended participation in any future integrated AI-enabled ecosystem. They are mostly buying the last dollars up to $18.50 and accepting the risk that if the transaction fails, the stock falls back toward a standalone number that is almost certainly lower. What the market is most likely misjudging now is not upside. It is the degree of downside hiding beneath a tight spread if the transaction wobbles.

The critical variables differ by time horizon. Over the next year, the important question is binary and practical: does the Altaris transaction close, and do interim results stay solid enough to protect the downside? Over the next three years, the key issue would be software mix recovery and whether the company can turn AI-enabled workflow rhetoric into software-led monetization. Over five years, the deepest question would be whether a broader integrated modeling ecosystem earns higher customer lifetime value without permanently sacrificing margins to services and implementation work. Those are not the same question. Public holders may not get to see the latter two answered, because the company may not remain public long enough.

The company would become a better investment under one of two conditions. Either the stock would need to fall materially below standalone value, creating a genuine margin of safety if the deal broke, or the standalone business would need to show several quarters in which software once again led growth and services supported rather than diluted the model. The original judgment should be revisited if three hard conditions appear: persistent sub-55% software mix, gross margin dropping back below 60%, or evidence that AI collaborations are not translating into either product adoption or commercial pricing power.

Bull and bear reasons

• Bull: FDA and EMA keep formalizing support for PBPK, mechanistic models, and NAMs, which directly helps the use cases where SLP’s software and toxicology collaborations sit.

• Bull: Q2 FY2026 brought software growth back to 9% and gross margin up to 66%, which argues the Q1 software drop was not purely structural.

• Bull: SLP still owns several scientifically trusted niche engines, and the March 2026 pharma AI collaborations embed AI inside validated workflows rather than selling generic automation.

• Bull: The company stays cash-generative despite the 2025 impairment, with operating cash flow of $18.1 million in fiscal 2025.

• Bull: If it closes, the Altaris transaction gives holders a defined near-term exit at $18.50 per share.

• Bear: Software revenue, the highest-quality part of the model, was still down 3% in the first half of FY2026, and clinical-operations software stayed weak across management commentary.

• Bear: Pro-ficiency clearly worsened the economic profile: management tied the 2025 gross-margin decline to its underperformance, and the company recorded $77.2 million of impairment charges.

• Bear: The stock offers very limited upside to the $18.50 deal price, but meaningful downside if the transaction breaks and the market reverts to standalone valuation.

• Bear: SLP lacks Certara’s scale and Schrödinger’s platform optionality, which makes it more vulnerable to being valued as a mixed software-services specialist rather than premium scientific software.

• Bear: The sale itself suggests private ownership and combination may surface more value than the public market was willing to capitalize in SLP’s standalone structure.

Pre mortem

Script one is the obvious case. The Altaris deal is delayed or fails in late 2026 or early 2027. The market reopens the standalone debate, Q3 or Q4 results show software mix still stuck near the mid-50s, gross margin slips back toward 60%, and investors stop anchoring on $18.50 cash. In that case the shares could fall back toward the $12–$14 area, especially if the market applies a 3x-ish revenue / sub-20x owner-earnings framework instead of a deal value. That would be a loss of roughly one-third from today’s price.

Script two is the slower version. Assume no deal, no collapse, but no real software re-acceleration either. By 2028 revenue is still growing only low single digits, services keep doing the heavy lifting, and the “integrated AI-enabled ecosystem” story produces pilot activity but little visible pricing power. In that case SLP could remain a good business with a permanently lower multiple, perhaps around 18x owner earnings rather than the premium growth multiples of 2020–2021. A stock that never regains the former narrative can still halve if earnings disappoint and the multiple stays compressed at the same time.

Final research conclusion

Simulations Plus is still a legitimate scientific software company with valuable tools, real regulatory relevance, and a credible place in model-informed drug development. The problem is not business existence. The problem is what a new public-market buyer is actually getting at $18.14 on 2026-06-25. At that price, most of the upside is already spoken for by Altaris’ $18.50 cash offer, while most of the fundamental uncertainties that weighed on the stock before the announcement still exist underneath the transaction. The software franchises may well be stronger than the Q1 scare implied, and Q2 did improve the picture. Even so, the company had not yet fully re-earned its former premium-growth status before the deal arrived.

If the question is whether SLP is worth owning here as a fresh equity purchase, my answer is no. The spread is too thin for the event risk, and the standalone valuation does not offer a margin of safety. What would change my mind is either a materially wider spread caused by technical rather than fundamental reasons, or a broken-deal price that falls into a genuine standalone buy zone while the software franchises remain intact. What worries me most is not a collapse in scientific relevance. It is the more ordinary but costly outcome in which a good niche company becomes a mediocre stock because the mix got messier and the market’s narrative ceiling moved lower.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: not suitable for the general investor

【Investment rating】

• Rating： Avoid
• One-line thesis： The stock is now a thin-spread cash-deal security, while the unresolved software-mix issue still leaves meaningful downside if the transaction breaks.
• Three price signals：
  • Ideal buy price： 【Ideal Buy Price】11.0–12.5 USD Basis: at least a 20% discount to my standalone conservative value framework, which assumes muted software recovery, owner earnings around $11–12 million, and a compressed 18x–20x owner-earnings multiple.
  • Acceptable hold price： 14.0–16.0 USD
  • Clearly overvalued price： 17.6 USD and above
• Current-price classification: clearly overvalued
• Whether to wait for a better price: yes. A buy would require either a broken-deal dislocation into roughly the $11–$13 range while software fundamentals remain intact, or evidence that the stock can be purchased below standalone value rather than at a deal-capped price. The opportunity cost of waiting is the small remaining spread to $18.50.
• Target holding horizon： not recommended for fresh purchase; if held for event reasons, the relevant horizon is deal closing in 6–12 months
• Expected annualized return: conservative about -12% to -9%; base about -6% to -3%; optimistic about -1% to +1% on a standalone basis from the current price. The merger-closing case offers only a low-single-digit absolute return to $18.50, not a normal long-term compounding profile.
• Max-loss risk： roughly 25%–35% if the Altaris deal fails and the market re-prices SLP on standalone fundamentals with software mix still weak
• Reassessment-trigger signals:
  • if software mix stays below 55% for two consecutive quarters
  • if gross margin falls back below 60% for two consecutive quarters
  • if clinical-operations software weakness spreads into discovery and development software
  • if the merger timetable slips materially without a clear procedural explanation
  • if AI collaboration programs fail to show any sign of productized monetization or customer expansion

【Valuation Range】

• current: 18.14 (close as of 2026-06-25)
• bear (conservative · ideal buy zone): [11.0, 12.5]
• base (fair · acceptable hold zone): [14.0, 16.0]
• bull (optimistic · above the clearly-overvalued line): [17.6, 18.6]

Key data tables

Selected financial history

The pattern behind the table is more important than the line items. Revenue kept growing, but margin quality deteriorated sharply after Pro-ficiency and the 2025 impairment made GAAP earnings unusable as a clean measure of operating performance. Cash flow stayed positive throughout.

Current peer snapshot

This is why SLP’s valuation and strategic position are delicate. It competes in an attractive lane, but it does not have Certara’s scale or Schrödinger’s option value. Its advantage is specialist credibility, which is powerful but easier to disrupt at the margin if execution slips.

Research uncertainties

There are three material blind spots in this report.

First, I do not have the full latest 10-Q balance-sheet detail in front of me, so the current net-cash estimate is anchored partly by market enterprise-value services and the 2025 annual report rather than a line-by-line February 2026 balance sheet. That is enough for directional judgment, but not for precision.

Second, the Altaris transaction changes the usefulness of traditional public-market valuation. The report therefore uses standalone valuation to assess downside and margin of safety, but the actual near-term stock path is driven more by deal mechanics than by a normal earnings-multiple process.

Third, customer-level churn, renewal rates, and product-by-product ARR are not disclosed in enough detail to prove exactly how temporary or structural the software weakness is. Management commentary points to clinical-operations softness and stronger discovery/development trends, but the external investor does not get a clean cohort-level map.

Sources

Primary and high-priority sources used in this report include Simulations Plus annual and quarterly disclosures, official company press releases, SEC filings, FDA and EMA policy pages, and peer company investor-relations disclosures and SEC filings. The most important ones for this report were:

• Simulations Plus 2025 Annual Report and prior SEC 10-K filings for 2024, 2023, and 2021.
• Simulations Plus Q1 and Q2 FY2026 earnings releases.
• Simulations Plus February and March 2026 press releases on FDA/NIEHS extensions, AI collaborations, and responsible AI in MIDD.
• Simulations Plus acquisition press releases for Cognigen, DILIsym, Lixoft, Immunetrics, Pro-ficiency, and the Altaris transaction.
• FDA and EMA official pages on MIDD, NAMs, PBPK, and mechanistic-model guidance.
• Certara and Schrödinger investor-relations and SEC materials for peer comparison.
• Market reference data for price history, closing price, market cap, enterprise value, and current peer prices.

Other tickers mentioned

• US CERT.US — principal listed peer in model-informed drug development and regulatory software
• US SDGR.US — strategic reference for computational drug-discovery platforms and AI-enabled scientific software
• US LLY.US — mentioned as a capital-markets reference point because its Ajax acquisition highlights the value investors place on differentiated computational drug-discovery assets
• US NVDA.US — mentioned as a technology partner in SLP’s broader AI workflow strategy

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.